Mondaq Asia Pacific: Food, Drugs, Healthcare, Life Sciences
Holding Redlich
Changes to Australian food labelling laws provide consumers with an increased understanding of the origin of their food.
Sparke Helmore Lawyers
The NT Supreme Court's decision in this matter was based primarily on the facts and circumstances of the Nitschke case.
King & Wood Mallesons
These Administration Measures are China's first normative document on administrating stem cell clinical research.
Ropes & Gray LLP
China will launch new reforms of its current review and approval system for drugs and medical devices, announced by China's State Council, in its August 18, 2015, circular Opinions Concerning the Reform of the Review and Approval System for Drugs and Medical Devices Issued by the State Council (the "Opinions", Guo Fa Notice [2015] No.44).
Ropes & Gray LLP
This paper offers analysis of the major changes, and provides insight into the organizational design and development of the regulatory affairs function at a medical device company in China.
Ropes & Gray LLP
The China Food and Drug Administration ("CFDA") recently published a draft circular to address the backlog of drug applications.
King & Wood Mallesons
The CFDA has drafted the Draft for Review to establish a scientific and highly effective regulatory system for cosmetics.
Ropes & Gray LLP
This year China's Advertising Law will see its first amendment in two decades.
King & Wood Mallesons
The National Development and Reform Commission (NDRC) published the Notice on Reinforcing Supervision over Drug Prices.
Sheppard Mullin Richter & Hampton
On May 4, 2015, the National Development and Reform Commission ("NDRC") and seven agencies including the National Health and Family Planning Commission and the Ministry of Human Resources and Social Security jointly published Opinions on Promoting Drug Price Reform (the "Opinions").
Jones Day
In May 2015, China's Food and Drug Administration ("CFDA") announced it is raising the registration fees imposed on pharmaceutical drugs and medical devices.
Ropes & Gray LLP
On May 19, 2015, the China Food and Drug Administration ("CFDA") unveiled the Technical Guideline Governing Medical Device Clinical Evaluation ("Guideline").
Ropes & Gray LLP
Beginning June 1, 2015, the vast majority drugs in China, except for narcotic and Type 1 psychotropic drugs, will be free from government-set pricing.
King & Wood Mallesons
The article discusses three highlights of the newly amended Drug Administration Law relating to registration and price.
Ropes & Gray LLP
China’s top legislature, the Standing Committee of National People’s Congress, recently approved the amendments (the "Amendments") to the Drug Administration Law.
Foley & Lardner
This post is the fifth in Foley’s blog series, "Realizing the Potential of Telemedicine in China," meant to address top issues facing U.S. companies looking to enter the Chinese telemedicine market.
Ropes & Gray LLP
The Center for Drug Evaluation (the "CDE") under the China Food and Drug Administration published final biosimilars guidance on February 28 with immediate effect.
King & Wood Mallesons
This article reviews highlights of the recent amendments and discusses the provisions of the Second Revised Amendment.
King & Wood Mallesons
This series of regulatory actions demonstrate efforts to strengthen the administration of medical devices and equipment.
Ropes & Gray LLP
The CFDA expects all device companies to comply with the New GMP and GSP rules as long as they intend to sell the products in China.
Most Popular Recent Articles
Vaish Associates Advocates
The Indian Medical Device industry has shown remarkable variation in its synthesis of demand and supply.
Medical centre operators commonly acquire an existing medical practice, where the doctor contracts to render services.
Singh & Associates
Indian Pharmaceutical Industry is at present, at its most progressive era where it has witnessed a robust growth over the past few years.
Singh & Singh Lall & Sethi (SSL&S)
The story continues……… those who have been reading our past newsletters will understand that in the patent landscape our focus has been pharmaceuticals
Singh & Associates
The recent controversy with respect to MNC Giant Nestle's Maggie noodles across the country has once again opened the Pandora box with respect to dual safety standards being followed by the MNC food company in the Country.
Singh & Associates
A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually.
Russin & Vecchi
Understanding Vietnamese laws and regulations concerning food can be a challenge. The confusion results from the lack of a unified food law. Instead, the government relies primarily on laws which regulate the quality of goods in general. There are also specific regulations that apply these laws to food products. This means that there are two sets of regulations, one covering goods in general, and the other covering food products, and they often overlap.
In India, access to health care facilities is still limited to a very small percentage of population owing mostly to unavailability of affordable drugs and treatment.
Singh & Associates
In today's era pharma industry is one of the most promising industry having huge profits, growth, knowledge and possibilities.
Singh & Associates
In a recent landmark decision taken on 1st June 2015, the Indian Patent Office rejected an application filed by US-based Abraxis BioScience relating to a new composition for Paclitaxel...
Article Search Using Filters
Related Topics
Popular Authors
Popular Contributors
Font Size:
Mondaq on Twitter